Ampersand-backed Alliance Pharma completed the acquisition of the drug development solutions business from LGC Group.

Ampersand-backed Alliance Pharma, a bioanalytical CRO, completed the acquisition of the drug development solutions business from LGC Group, a provider of scientific testing, specialist analytical and diagnostic laboratory services. KKR will invest in the combined business alongside Ampersand Capital. Financial terms were not disclosed. "I am proud of the scientific and commercial achievements delivered by the DDS business over the years, supporting customers in their mission to develop new medicines and products to improve the quality of life. I am confident that as part of the Alliance organisation, the DDS team will be well positioned for on-going success as part of a global business focused on bioanalytical and materials sciences activities," Euan O'Sullivan, LGC President and CEO.